Sexually Transmitted Diseases

New review article outlines the evidence and future work that needs to be done with regards to doxycycline post-exposure prophylaxis (doxy-PEP).

Investigators recently noted that despite a decrease in adolescent hospital visits during the height of the pandemic, there was an increase in sexually transmitted infections (STIs) in this population group.

The latest data on sexually transmitted infections (STI) shows a large increase in syphilis incidence rates year-over year, where others were either flat or saw a slight decrease. The report also shows an ongoing rise of syphilis cases over the long-term.

New challenges in the fight against gonorrhea in the US.

Doxycycline postexposure prophylaxis (PEP) has reduced STIs among men who have sex with men, but poor adherence marred trial results with women.

A new study warns an increase in costs could lead to new infections.

Early treatment of the antiviral tecovirimat (TPOXX) could inhibit virus replication by more than 90%.

With an increased incidence of this sexually transmitted infection, a review of an older antibiotic for treatment has shown some clinical benefits in other countries.

The vaccine has been approved since late 2019 for adults age 18 and older.

The phase 1/2 trial evaluating EBT-101 dosed its first patient in September 2022.

The update refreshes the organization's 2022 guidance on HIV, viral hepatitis, and STI prevention, diagnosis, treatment, and care for key populations, focusing on people in prisons and other closed settings.

When taken within 3 days, doxycycline given post-exposure (doxy-PEP) decreased the incidence rates of syphilis, gonorrhea, and chlamydia significantly.

February 7 is National Black HIV/AIDS Awareness Day (#NBHAAD). In observance, we're recapping stories to raise awareness and work toward ending HIV/AIDS disparities in Black communities.

Sexually transmitted infections (STIs) received little attention during the pandemic, but the truth is the STIs did not stop infection increases shortly after the quarantine.

Genital herpes (HSV-2) affects quality-of-life but also causes substantial economic losses, especially in low- and middle-income countries.

HIV PrEP prescriptions increased from 0 among people who use injection drugs, but overall PrEP uptake remains low.

Herpes simplex viruses are chronic infections that underscore racial and ethnic disparities and are afflicting adolescents in increasing numbers.

Yasaswi Kislovskiy, MD, MSc, specialized in reproductive infectious disease to advocate for gender equity in health care.

Gonococcal septic polyarthritis is an uncommon manifestation of N gonorrhoeae infection, but has increased by about 40% in recent years.

This will include 3 trials to examine the therapy in different formulations in HIV studies.

There are a number of programs designed to help lower rates of infection and transmission amongst this industry's workforce in South Africa.

Investigators noted 2 distinct phases of HIV virus levels, meaning any infected cells that survive treatment can become latent, only to reignite HIV infection after antiretroviral therapy is stopped.

Taking into account the first PrEP pill was FDA approved in 2012, a clinician reflects on its significance and where the shortcomings of education and utility of it needs to be fortified.

WHO guidelines on HIV, hepatitis and STIs focus on populations with high risk of infections but low inclusion in prevention and treatment programs.

The study was longitudinal in nature, comparing at-risk people who became infected with HIV to at-risk people who did not.

Expanding Medicaid and reducing stigma can bolster equitable HIV PrEP access, Dr. Patrick Sullivan says.

After widespread implementation of HIV pre-exposure prophylaxis (PrEP) among gay and bisexual men in Australia, population-level incidence of chlamydia and gonorrhea stabilized, allaying fears that PrEP would lead to a rise in STIs, a recent study found.

After 5 years of treatment, fostemsavir improved immunologic response and virologic outcome in patients with highly resistant HIV infection.

HIV epidemics are emerging among key populations in the Middle East and North Africa, and the region ranks lowest globally in response indicators.